| Literature DB >> 32765011 |
Fatemeh Nouri1, Pezhman Karami2, Omid Zarei3, Faezeh Kosari3, Mohammad Yousef Alikhani2, Eghbal Zandkarimi4, Ebrahim Rezazadeh Zarandi5, Mohammad Taheri2.
Abstract
INTRODUCTION: The prevalence of nosocomial infections in patients hospitalized to three hospitals of Shahid Beheshti, Farshchian, and Be' saat in Hamadan was investigated for 2 years (2018 to 2020).Entities:
Keywords: CSF; UTI; antimicrobial resistance pattern; nosocomial infections; trachea
Year: 2020 PMID: 32765011 PMCID: PMC7369413 DOI: 10.2147/IDR.S259252
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
The Most Prevalent Bacterial Isolates According to Their Sampling Sites
| UTI (1394 Isolates) | Tracheal (588 Isolates) | ||||
|---|---|---|---|---|---|
| Isolates | No. | Percentage (%) | Isolates | No. | Percentage (%) |
| 832 | 59.6 | 164 | 27.8 | ||
| 139 | 9.9 | 118 | 20.06 | ||
| 71 | 5.09 | 97 | 16.4 | ||
| 70 | 5.02 | 57 | 9.6 | ||
| 52 | 3.7 | 52 | 8.8 | ||
| Micrococcus | 35 | 2.5 | 27 | 4.5 | |
| Enterobacter | 31 | 2.2 | Enterobacter | 10 | 1.7 |
| 30 | 2.15 | 9 | 1.5 | ||
| 18 | 1.2 | 9 | 1.5 | ||
| Alkaligenes | 18 | 1.2 | |||
| 15 | 1.07 | 11 | 68.7 | ||
| 13 | 0.09 | 3 | 18.7 | ||
| 9 | 0.06 | 1 | 6.25 | ||
| Enterococcus | 9 | 0.06 | 1 | 6.25 | |
Antibiotic Resistance Profile of Organisms Isolated from UTI Infections
| Antibiotics Disk | FEP | GM | AN | SAM | SXT | FM | CN | CRO | LEV | CZ | IMI | MEN | PTZ | OFX | V |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21 | 24 | 43 | 30 | 1 | 60 | 81 | 2 | 54 | 4 | 42 | 2 | 30 | 16 | 26 | |
| (15.1%) | (17.2%) | (30.9%) | (21.5%) | (0.7%) | (43.1%) | (58.2%) | (1.49%) | (38.8%) | (2.8%) | (30.2%) | (1.4%) | (21.5%) | (11.5%) | (18.7%) | |
| 3 | 2 | 0 | 1 | 19 | 5 | 0 | 6 | 2 | 14 | 0 | 0 | 2 | 2 | 9 | |
| (4.2%) | (2.8%) | 0 | (1.4%) | (27.1%) | (7.1%) | 0 | (8.5%) | (2.8%) | (20%) | 0 | 0 | (2.8%) | (2.8%) | (12.8%) | |
| 3 | 4 | 2 | 1 | 16 | 3 | 0 | 8 | 3 | 2 | 1 | 0 | 4 | 2 | 4 | |
| (5.7%) | (7.6%) | (3.8%) | (1.9%) | (30.7%) | (5.7%) | 0 | (15.3%) | (5.7%) | (3.8%) | (1.9%) | 0 | (7.6%) | (3.8%) | (7.6%) | |
| 3 | 8 | 4 | 1 | 1 | 6 | 1 | 10 | 0 | 5 | 0 | 3 | 0 | 1 | 0 | |
| (9.6%) | (25.8%) | (12.9%) | (3.2%) | (3.2%) | (19.3%) | (3.2%) | (32.2%) | 0 | (16.1%) | 0 | (9.6%) | 0 | (3.2%) | 0 | |
| 19 | 18 | 24 | 12 | 34 | 34 | 2 | 24 | 4 | 12 | 5 | 15 | 12 | 14 | 0 | |
| (27.1%) | (25.7%) | (34.2%) | (17.1%) | (48.5%) | (48.5%) | (2.8%) | (34.2%) | (5.7%) | (17.1%) | (7.1%) | (21.4%) | (17.1%) | (20%) | 0 | |
| 83 | 127 | 54 | 8 | 444 | 98 | 11 | 302 | 14 | 209 | 4 | 20 | 37 | 145 | 0 | |
| (9.9%) | (15.2%) | (6.4%) | (0.9%) | (53.3%) | (11.7%) | (1.3%) | (36.2%) | (1.6%) | (25.1%) | (0.4%) | (2.4%) | (4.4%) | (17.4%) | 0 | |
| 10 | 16 | 20 | 2 | 21 | 20 | 3 | 16 | 2 | 16 | 1 | 16 | 3 | 8 | 1 | |
| (33.3%) | (53.3%) | (66.6%) | (6.6%) | (70%) | (66.6%) | (10%) | (53.3%) | (6.6%) | (53.3%) | (3.3%) | (53.3%) | (10%) | (26.6%) | (3.3%) | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 3 | 0 | 3 | 2 | 1 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | (30.7%) | (7.6%) | (23%) | 0 | (23%) | (15.3%) | (7.6%) | 0 |
Abbreviations: FEP, cefepime; GM, gentamicin; AN, amikacin; SAM, sulbactam; SXT, trimethoprim-sulfamethoxazole; FM, nitrofurantoin; CN, cefotetan; CRO, ceftriaxone; LEV, levofloxacin; CZ, cefazolin; IMI, imipenem; MEN, meropenem; PTZ, piperacillin/tazobactam; OFX, ofloxacin; V, vancomycin.
Antibiotic Resistance Profile of Organisms Isolated from Tracheal Infections
| Antibiotics Disk | CP | CAZ | FEP | GM | AN | SAM | SXT | CN | CRO | LEV | AK | CZ | IMI | MEN | PTZ | V |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 95 | 120 | 114 | 58 | 73 | 30 | 8 | 23 | 56 | 42 | 9 | 1 | 72 | 114 | 96 | 10 | |
| (57.9%) | (73.1%) | (69.5%) | (35.3%) | (44.5%) | (18.2%) | (4.8%) | (14.0%) | (34.1%) | (25.60%) | (5.48%) | (0.6%) | (43.9%) | (69.5%) | (58.5%) | (6.09%) | |
| 20 | 7 | 4 | 0 | 0 | 0 | 9 | 0 | 6 | 2 | 0 | 10 | 2 | 8 | 7 | 1 | |
| (38.4%) | (13.4%) | (7.6%) | 0 | 0 | 0 | (17.3%) | 0 | (11.5%) | (3.8%) | 0 | (19.2%) | (3.8%) | (15.3%) | (13.4%) | (1.9%) | |
| 8 | 8 | 6 | 4 | 0 | 1 | 5 | 2 | 2 | 3 | 0 | 1 | 4 | 0 | 0 | 3 | |
| (29.6%) | (29.6%) | (22.2%) | (14.8%) | 0 | (3.7%) | (18.5%) | (7.4%) | (7.4%) | (11.1%) | 0 | (3.7%) | (14.8%) | 0 | 0 | (11.1%) | |
| 3 | 5 | 3 | 2 | 2 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 5 | 5 | 5 | 0 | |
| (27.2%) | (45.4%) | (27.2%) | (18.1%) | (18.1%) | (9.0%) | (9.0%) | 0 | (9.0%) | (9.09%) | (9.0%) | (9.0%) | (45.4%) | (45.4%) | (45.4%) | 0 | |
| 10 | 40 | 50 | 19 | 43 | 15 | 8 | 13 | 26 | 8 | 4 | 1 | 43 | 46 | 41 | 0 | |
| (10.3%) | (41.2%) | (51.5%) | (19.5%) | (44.3%) | (15.4%) | (8.2%) | (13.4%) | (26.8%) | (8.2%) | (4.1%) | (1.0%) | (44.3%) | (47.4%) | (42.2%) | 0 | |
| 30 | 20 | 20 | 17 | 4 | 3 | 6 | 0 | 17 | 9 | 0 | 0 | 14 | 10 | 27 | 0 | |
| (52.6%) | (35.0%) | (35.0%) | (29.8%) | (7.01%) | (5.2%) | (10.5%) | 0 | (29.8%) | (15.7%) | 0 | 0 | (24.5%) | (17.5%) | (47.3%) | 0 | |
| 81 | 101 | 93 | 45 | 91 | 14 | 6 | 9 | 53 | 38 | 11 | 0 | 72 | 96 | 94 | 1 | |
| (68%) | (85.5%) | (78.8%) | (38.1%) | (77.1%) | (11.8%) | (5.0%) | (7.6%) | (44.9%) | (32.2%) | (9.3%) | 0 | (61.0%) | (81.3%) | (79.6%) | (0.84%) | |
| 3 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 2 | 1 | 0 | 1 | 2 | 0 | 0 | |
| (37.5%) | 0 | 0 | 0 | 0 | 0 | (25%) | 0 | (25%) | (25%) | (12.5%) | 0 | (12.5%) | (25%) | 0 | 0 |
Abbreviations: CP, ciprofloxacin; CAZ, ceftazidime; FEP, cefepime; GM, gentamicin; AN, amikacin; SAM, sulbactam; SXT, trimethoprim-sulfamethoxazole; FM, nitrofurantoin; CN, cefotetan; CRO, ceftriaxone; LEV, levofloxacin; CZ, cefazolin; IMI, imipenem; MEN, meropenem; PTZ, piperacillin/tazobactam; OFX, ofloxacin; V, vancomycin.
Antibiotic Resistance Profile of Organisms Isolated from CSF Infections
| Antibiotics Disk | FEP | MEN | IMI | CRO | AN | PTZ | SXT | SAM | LEV | GM | CAZ | CP |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 3 | 3 | 3 | |
| 0 | (66.6%) | 0 | 0 | 0 | 0 | (66.6%) | 0 | 0 | (100%) | (100%) | (100%) | |
| 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 4 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 50 | 0 | 0 | (25%) | 0 | (100%) | |
| 0 | 2 | 0 | 2 | 0 | 0 | 3 | 0 | 0 | 1 | 2 | 1 | |
| 0 | (9.5%) | 0 | (9.5%) | 0 | 0 | (14.2%) | 0 | 0 | (4.7%) | (9.5%) | (4.7%) | |
| 0 | 0 | 1 | 1 | 0 | 0 | 2 | 1 | 0 | 1 | 2 | 3 | |
| 0 | 0 | (33.3%) | (33.3%) | 0 | 0 | (66.6%) | (33.3%) | 0 | (33.3%) | (66.6%) | (100%) | |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | (100%) | 0 | 0 | 0 | 0 | 0 |
Abbreviations: CP, ciprofloxacin; CAZ, ceftazidime; FEP, cefepime; GM, gentamicin; AN, amikacin; SAM, sulbactam; SXT, trimethoprim-sulfamethoxazole; CRO, ceftriaxone; LEV, levofloxacin; IMI, imipenem; MEN, meropenem; PTZ, piperacillin/tazobactam.